LENZ Therapeutics (LENZ) vs Rani Therapeutics (RANI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rani Therapeutics (RANI) has outperformed LENZ Therapeutics (LENZ) over the past year, gaining 61.6% versus a loss of 92.7%. Over five years, RANI leads with a -96.0% price change compared with -96.1% for LENZ. LENZ Therapeutics is the larger company by market cap ($113.4 million vs $112.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LENZ | RANI |
|---|---|---|
| Share price | $3.61 | $0.8004 |
| Market cap | $113.43M | $112.47M |
| 1-day change | +2.27% | +1.06% |
| YTD return | -77.94% | -41.33% |
| 1-year return | -92.74% | +61.63% |
| 5-year return | -96.05% | -95.98% |
| EPS (TTM) | $-4.13 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $46.75 | $3.87 |
| 52-week low | $3.35 | $0.445 |
| Distance from 52-week high | -92.28% | -79.32% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +564.82% | +799.55% |
| Average volume | 833.64K | 743.68K |
| Shares outstanding | 31.42M | 115.42M |
| Employees | 152 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RANI has outperformed LENZ by 154.4 percentage points over the past year.
About LENZ Therapeutics
LENZ stock →LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 152 employees
About Rani Therapeutics
RANI stock →Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
LENZ vs RANI FAQ
Which is bigger, LENZ Therapeutics or Rani Therapeutics?
LENZ Therapeutics (LENZ) is larger, with a market capitalization of $113.43M compared with $112.47M for Rani Therapeutics (RANI).
Which stock has performed better over the past year, LENZ or RANI?
RANI returned +61.63% over the past 12 months, compared with -92.74% for LENZ (price return, excluding dividends). Past performance does not predict future results.
Are LENZ Therapeutics and Rani Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for LENZ Therapeutics and Biotechnology: Pharmaceutical Preparations for Rani Therapeutics.